Introduction to Real Life Outcomes

What is/are Real Life Outcomes?

Real Life Outcomes - The end of the chapter returns to the case studies presented in Chapter 11 and describes the real-life outcomes followed by questions for class discussion. ^[1] It is associated with worse social functioning and quality of life; however, the influence on real-life outcomes is unknown. ^[2] PURPOSE To evaluate real-life outcomes of XEN45 stent surgery including bleb needling (BN) and surgical bleb revision (SBR). ^[3] Conclusions: In the study, we showed real-life outcomes of sorafenib for disease control in heavily pretreated adult patients with metastatic osteosarcoma. ^[4] Ultimately, which tools should we recommend to discriminate real-life outcomes in AD? The current trend to dissociate objective and subjective items render difficult a global assessment on how the efficacy of a drug is perceived both by doctors and patients. ^[5] The end of the chapter returns to the case studies presented in Chapter 9, describes the real-life outcomes, and presents questions for discussion. ^[6] Chapter 14 returns to the case studies presented in Chapter 13 and describes the real-life outcomes along with questions for class discussion. ^[7] The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. ^[8] We argue that test-taking behavior is not a nuisance factor that may confound measurement, but an aspect that provides important information on how examinees approach tasks, which is relevant for real-life outcomes. ^[9] This study compared real-life outcomes of the first affected eye (1st eye) and the last affected eye (2nd eye) after anti-vascular endothelial growth factor (anti-VEGF) treatment. ^[10] Conclusions: In this study, we showed real-life outcomes of the patients with EGFR-mutant metastatic non-small cell lung cancer. ^[11] Chapter 16 returns to the case studies presented in Chapter 15 and describes the real-life outcomes along with questions for class discussion. ^[12] This study aimed to evaluate the real-life outcomes of DF treatment. ^[13] In the GARLIT (GalcanezumAb in Real Life in ITaly) study, we showed the 6-month real-life outcomes in patients receiving galcanezumab on direct hospital dispensation before the Italian Medicines Agency had defined reimbursement criteria [2]. ^[14] Moreover, people with and without disabilities have differing opinions on the impact of the ADA, suggesting that what is conveyed to the public and the impact of the ADA on real-life outcomes of PWD are sometimes misaligned. ^[15] However, there is little published data on real life outcomes of these challenges. ^[16]

case studies presented

The end of the chapter returns to the case studies presented in Chapter 11 and describes the real-life outcomes followed by questions for class discussion. ^[1] The end of the chapter returns to the case studies presented in Chapter 9, describes the real-life outcomes, and presents questions for discussion. ^[2] Chapter 14 returns to the case studies presented in Chapter 13 and describes the real-life outcomes along with questions for class discussion. ^[3] Chapter 16 returns to the case studies presented in Chapter 15 and describes the real-life outcomes along with questions for class discussion. ^[4]

endothelial growth factor

This study compared real-life outcomes of the first affected eye (1st eye) and the last affected eye (2nd eye) after anti-vascular endothelial growth factor (anti-VEGF) treatment. ^[1]